Cancer vaccine NY-ESO-1 (CSL/Ludwig Institute for Cancer Research)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCancer vaccine NY-ESO-1 (CSL/Ludwig Institute for Cancer Research)
Drug Alias Name癌症疫苗NY-ESO-1 - CSL/路德维格癌症研究所ESO-1 IMX,ISCOMATRIX ESO1 Therapy,Melanoma vaccine NY-ESO-1,NY-ESO-1 ISCOMATRIX vaccineNY-ESO1 protein/ISCOM adjuvant
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustraliaUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCsl LtdLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCsl LtdLudwig Institute For Cancer Research
Active IndicationsN/A
Inactive IndicationsMelanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A